Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers

被引:54
作者
Gong, MC
Chang, SS
Sadelain, M
Bander, NH
Heston, WDW
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA
[3] Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Dept Urol, New York, NY USA
关键词
monoclonal antibody; immunotherapy; angiogenesis; gene therapy;
D O I
10.1023/A:1006308826967
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein that is expressed by prostate epithelial cells. PSMA-specific monoclonal antibodies have been utilized to characterize the biologic function and in vivo biodistribution of PSMA. PSMA is an attractive target protein for monoclonal antibody directed imaging or therapeutics for prostate cancer since its expression is relatively restricted to prostate epithelial cells and is over-expressed in prostate cancer, including in advanced stages. Currently, clinical usage of PSMA specific monoclonal antibodies has been limited to diagnostic immunohistochemistry and imaging of patients with prostate cancer. Novel applications for these antibodies will be discussed.
引用
收藏
页码:483 / 490
页数:8
相关论文
共 39 条
[1]  
BARRETT AJ, 1992, ENZYME NOMENCLATUR S, V4
[2]  
Barrett Alan J., 1997, European Journal of Biochemistry, V250, P1
[3]  
Bostwick DG, 1998, CANCER-AM CANCER SOC, V82, P2256, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO
[4]  
2-S
[5]   Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase [J].
Carter, RE ;
Feldman, AR ;
Coyle, JT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (02) :749-753
[6]  
Chang SS, 2000, CANCER-AM CANCER SOC, V88, P407, DOI 10.1002/(SICI)1097-0142(20000115)88:2<407::AID-CNCR23>3.3.CO
[7]  
2-S
[8]  
Chang SS, 1999, CANCER RES, V59, P3192
[9]  
CHANG SS, 1999, IN PRESS CLIN CANC R
[10]  
Elgamal AAA, 1998, PROSTATE, V37, P261, DOI 10.1002/(SICI)1097-0045(19981201)37:4<261::AID-PROS8>3.0.CO